Literature DB >> 30023394

The search for surrogate endpoints for immunotherapy trials.

Marc Buyse1,2, Tomasz Burzykowski2,3, Everardo D Saad3.   

Abstract

Year:  2018        PMID： 30023394      PMCID： PMC6035998          DOI： 10.21037/atm.2018.05.16

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

1.  Challenges of guarantee-time bias.

Authors:  Anita Giobbie-Hurder; Richard D Gelber; Meredith M Regan
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

2.  Meta-analysis for the evaluation of potential surrogate markers.

Authors:  M J Daniels; M D Hughes
Journal:  Stat Med       Date:  1997-09-15       Impact factor: 2.373

Review 3.  The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Authors:  Vinay Prasad; Chul Kim; Mauricio Burotto; Andrae Vandross
Journal:  JAMA Intern Med       Date:  2015-08       Impact factor: 21.873

Review 4.  Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.

Authors:  Marc Buyse; Geert Molenberghs; Xavier Paoletti; Koji Oba; Ariel Alonso; Wim Van der Elst; Tomasz Burzykowski
Journal:  Biom J       Date:  2015-02-12       Impact factor: 2.207

5.  Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques.

Authors:  Sjouke Vandenberghe; Luc Duchateau; Leen Slaets; Jan Bogaerts; Stijn Vansteelandt
Journal:  Stat Methods Med Res       Date:  2017-04-20       Impact factor: 3.021

6.  Advantages of a Truly Open-Access Data-Sharing Model.

Authors:  Monica M Bertagnolli; Oliver Sartor; Bruce A Chabner; Mace L Rothenberg; Sean Khozin; Charles Hugh-Jones; David M Reese; Martin J Murphy
Journal:  N Engl J Med       Date:  2017-03-23       Impact factor: 91.245

7.  Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.

Authors:  Sirisha L Mushti; Flora Mulkey; Rajeshwari Sridhara
Journal:  Clin Cancer Res       Date:  2018-01-11       Impact factor: 12.531

8.  Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Authors:  Qian Shi; Christopher R Flowers; Wolfgang Hiddemann; Robert Marcus; Michael Herold; Anton Hagenbeek; Eva Kimby; Howard Hochster; Umberto Vitolo; Bruce A Peterson; Emmanuel Gyan; Michele Ghielmini; Tina Nielsen; Sabine De Bedout; Tommy Fu; Nancy Valente; Nathan H Fowler; Eva Hoster; Marco Ladetto; Franck Morschhauser; Emanuele Zucca; Gilles Salles; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

Review 9.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321
  9 in total
  2 in total

1.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.

Authors:  Casey Quinn; Louis P Garrison; Anja K Pownell; Michael B Atkins; Gérard de Pouvourville; Kevin Harrington; Paolo Antonio Ascierto; Phil McEwan; Samuel Wagner; John Borrill; Elise Wu
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

Review 2.  Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects.

Authors:  Haiqing Isaac Dai; Yulia Vugmeyster; Naveen Mangal
Journal:  Clin Pharmacol Ther       Date:  2020-08-02       Impact factor: 6.875
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.